Recombinant Human OX40 / TNFRSF4 / CD134 Protein, His-Tag, 100µg

Background
Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5.

Source
Recombinant Human OX40 Protein, His Tag (MALS verified) (OX0-H5224) is expressed from human 293 cells (HEK293). It contains AA Leu 29 - Ala 216 (Accession # P43489-1).
Predicted N-terminus: Leu 29

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 22.0 kDa. The protein migrates as 35-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Blockade of OX40/OX40L signaling using anti-OX40L alleviates murine lupus nephritis"
Zhao, Li, Feng et al
Eur J Immunol (2024)
(2) "Soluble Plasma Proteins of Tumor Necrosis Factor and Immunoglobulin Superfamilies Reveal New Insights into Immune Regulation in People with HIV and Opioid Use Disorder"
Ghanta, Dang, Nelson et al
Vaccines (Basel) (2024) 12 (5)
(3) "Breaking the Tumor Chronic Inflammation Balance with a Programmable Release and Multi-Stimulation Engineering Scaffold for Potent Immunotherapy"
Liang, Li, Wu et al
Adv Sci (Weinh) (2024)
Showing 1-3 of 2138 papers.

Citations

(1) "Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist"
Authors: Upadhyaya P, Lahdenranta J, Hurov K, et al.
Journal: Journal for immunotherapy of cancer 2021
Application: SPR
(2) "Affinity maturation of antibodies by combinatorial codon mutagenesis versus error-prone PCR"
Authors: Simons JF, Lim YW, Carter KP, et al
Journal: Mabs 2020
Application: Flow cytometry
(3) "Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy"
Authors: Fromm G, et al
Journal: J ImmunoTher Cancer 2018
Application: SPR